- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01392794
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet
July 11, 2011 updated by: Astellas Pharma Inc
Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion Without Water
A study to compare time-course changes of plasma concentration of YM060 after intake of conventional tablet and orally-disintegrating tablet.
Orally-disintegrating tablets will be administered without water.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 44 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- healthy assessed by the principal investigator or sub-investigators
- non-smoking or stop smoking at least 90 days before the study
- body weight: over 50.0kg and less than 80.0kg
- body mass index (BMI): over 17.6 and less than 26.4
Exclusion Criteria:
- participated in another clinical trial (including a post-marketing clinical study) within 120 days before the study
- donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or blood components within 14 days before the study
- received any drugs within 7 days before the study or going to receive any drugs
- deviance from normal range in vital signs (blood pressure, pulse rate, and body temperature) or 12-lead ECG
- deviance from normal range in lab-tests
- history of drug allergy
- history or current diagnosis of stomach, small intestine or large intestine diseases
- history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
- history or current diagnosis of colitis ischemic
- history or current diagnosis of hepatic diseases
- history or current diagnosis of cardiovascular diseases
- history or current diagnosis of respiratory diseases
- history or current diagnosis of malignant tumor
- received ramosetron tablet
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: orally-disintegrating (OD) tablet precedence group
|
oral, without water
Other Names:
|
Experimental: conventional tablet precedence group
|
oral, without water
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve of YM060 plasma concentration -time curve
Time Frame: up to 24 hours after administration
|
up to 24 hours after administration
|
Maximal concentration of YM060 plasma concentration
Time Frame: up to 24 hours after administration
|
up to 24 hours after administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECG
Time Frame: up to 24 hours after administration
|
up to 24 hours after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
July 11, 2011
First Submitted That Met QC Criteria
July 11, 2011
First Posted (Estimate)
July 13, 2011
Study Record Updates
Last Update Posted (Estimate)
July 13, 2011
Last Update Submitted That Met QC Criteria
July 11, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 060-CL-208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on YM060
-
Astellas Pharma IncCompletedIrritable Bowel SyndromeJapan
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedIrritable Bowel SyndromePoland, Germany, Bulgaria, Ukraine, Estonia, Russian Federation, Czech Republic, Lithuania
-
Astellas Pharma IncCompletedDiarrhea-predominant Irritable Bowel SyndromeJapan
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration of YM060Japan
-
Astellas Pharma IncCompletedDiarrhea-predominant Irritable Bowel SyndromeJapan
-
Astellas Pharma IncCompletedDiarrhea-predominant Irritable Bowel SyndromeJapan
-
Astellas Pharma IncCompletedIrritable Bowel SyndromeJapan
-
Astellas Pharma IncCompletedIrritable Bowel SyndromeJapan
-
Astellas Pharma IncCompletedIrritable Bowel SyndromeJapan